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ABSTRACT
Prostaglandins(PGs)areessentialsignalingfactorsinbonemechanotransduction.Inanimals,inhibitionoftheenzymeresponsibleforPG
synthesis (cyclooxygenase) by nonsteroidal anti-inflammatory drugs (NSAIDs) blocks the bone-formation response to loading when
administered before, but not immediately after, loading. The aim of this proof-of-concept study was to determine whether the timing of
NSAID use influences bone mineral density (BMD) adaptations to exercise in humans. Healthy premenopausal women (n¼73) aged 21
to 40 years completed a supervised 9-month weight-bearing exercise training program. They were randomized to take (1) ibuprofen
(400mg) before exercise, placebo after (IBUP/PLAC), (2) placebo before, ibuprofen after (PLAC/IBUP), or (3) placebo before and after
(PLAC/PLAC)exercise.RelativechangesinhipandlumbarspineBMDfrombeforetoafterexercisetrainingwereassessedusingaHologic
Delphi-W dual-energy X-ray absorptiometry (DXA) instrument. Because this was the first study to evaluate whether ibuprofen use affects
skeletal adaptations to exercise, only women who were compliant with exercise were included in the primary analyses (IBUP/PLAC,
n¼17; PLAC/PLAC, n¼23; and PLAC/IBUP, n¼14). There was a significant effect of drug treatment, adjusted for baseline BMD, on the
BMD response to exercise for regions of the hip (total, p<.001; neck, p¼.026; trochanter, p¼.040; shaft, p¼.019) but not the
spine (p¼.242). The largest increases in BMD occurred in the group that took ibuprofen after exercise. Total-hip BMD changes
averaged –0.2% 1.3%, 0.4% 1.8%, and 2.1% 1.7% in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. This
preliminary study suggests that taking NSAIDs after exercise enhances the adaptive response of BMD to exercise, whereas taking
NSAIDs before may impair the adaptive response.  2010 American Society for Bone and Mineral Research.
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Introduction
P
rostaglandin E2 (PGE2) increases in bone in response to
mechanical loading and appears to be an essential
intermediate in the signaling pathway for bone formation (i.e.,
mechanotransduction).
(6,34,36) The key enzyme involved in the
production of PGE2 and other prostaglandins is cyclooxygenase
(COX). Inhibition of COX with nonsteroidal anti-inflammatory
drugs (NSAIDs) markedly diminishes the bone-formation
response to mechanical stress in laboratory animals and cultured
osteoblasts.
(5,7–9,20) This effect has been observed in response to
bothnonselective
(5,7–9)andCOX-2selectiveinhibitors,
(9,20)which
is consistent with the observation that mechanotransduction is
mediated primarily through the activation of COX-2.
(2) Impor-
tantly, the timing of NSAID administration appears to be a key
determinant of the bone-formation response. Formation is signi-
ficantly attenuated when NSAIDs are administered before
mechanical loading, but not when they are administered
after.
(7,20)
An important limitation of these studies is that they evaluated
the bone-formation response to acute mechanical loading only.
Thus it is not clear whether the usual effects of repeated bouts of
mechanical loading (i.e., exercise training) to increase bone
mineral density (BMD) and strength are impaired by NSAID use.
Chronic exposure to NSAIDs has been found to have deleterious
effects on bone in rats restricted to usual cage activity,
(30,32)
although this is not a consistent observation.
(12) Because PGE2
plays a role in the activation of both bone formation and
resorption, chronic NSAID use could have antiformation and/or
antiresorptive actions, and the net effect on BMD could be
beneficial, detrimental, or neutral.
(28) In this context, it is not
surprisingthatthehumancohortstudiesthathaveexaminedthe
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1415associations of NSAID use with BMD, markers of bone turnover,
or fracture risk have yielded mixed results.
(3,4,19,23,29,35) Impor-
tantly, a consistent finding among studies of animals is that
NSAIDs markedly diminish the bone-formation response to
mechanical stress when administered before loading.
Because there have been no studies, in animals or humans, of
the effects of NSAID use on skeletal adaptations to exercise, this
study was considered a preliminary, proof-of-concept investiga-
tion. The primary aim was to determine whether ibuprofen, a
commonly used nonselective COX inhibitor, attenuates the BMD
adaptations to exercise training. A second aim was to determine
whether the timing of ibuprofen use (ie, before versus after
exercise) influences the adaptive response. Based on the studies
of the timing of NSAID administration on the bone-formation
response to a single loading bout in animals,
(7,20) we hypo-
thesized that taking ibuprofen before exercise sessions would
attenuate the increases in BMD in response to exercise training
when compared with taking ibuprofen after exercise sessions or
with placebo treatment.
Materials and Methods
Study design and participants
This was a randomized, double-blinded, placebo-controlled
study of the effects of ibuprofen use and the timing of use
relative to performance of exercise on the BMD response to a 9-
month exercise training program. Although conducted as a
randomized, controlled trial, this was a proof-of-concept study
to determine whether there is translation of the skeletal effects
of NSAIDS in rodents
(7,20) to human physiology. Volunteers
provided written informed consent to participate, and the study
was approved by the Colorado Multiple Institutional Review
Board.
The participants were healthy, eumenorrheic women aged 21
to 40 years. Eumenorrheic status was defined as having a
menstrual cycle length of 25 to 31 days and at least 10 cycles in
the preceding year. Women on progestin-only contraceptive
therapy were excluded, but other hormonal contraceptive
therapy was allowed. Other inclusion criteria were exercising less
than 3 days per week at moderate to high intensity; body mass
index (BMI) of less than 30kg/m
2; nonsmoker for more than
2 years; not pregnant or lactating; no NSAID intolerance or
sensitivity; typical NSAID use less than 3 days per month; no use
of drugs that affect bone metabolism; serum thyroid-stimulating
hormone concentration of 0.5 to 5.0mU/mL; hematocrit of 30%
orgreater;serumcreatinineconcentrationoflessthan1.4mg/dL;
no history of ulcers, gastrointestinal bleeding, gastroesophageal
reflux disease, thrombocytopenia, or bleeding disorders; and no
known liver disease, kidney disease, cardiovascular disease,
diabetes, or hypertension. Volunteers who met eligibility criteria
and were willing to continue in the study (n¼95) were
randomized to three treatment arms before starting the
supervised 9-month exercise training program: (1) ibuprofen
before exercise, placebo after exercise (IBUP/PLAC, n¼31), (2)
placebo before exercise, placebo after exercise (PLAC/PLAC,
n¼31), and (3) placebo before exercise, ibuprofen after exercise
(PLAC/IBUP, n¼33).
Drug intervention
Participants took two study capsules, one before exercise and
one after, on each day of supervised exercise. The capsules were
prepared by a local pharmacy (Belmar Pharmacy, Lakewood, CO,
USA) and contained either ibuprofen 400mg or inactive
ingredients. All capsules were identical in appearance, with
the exception that capsules taken 1 to 2 hours before the
exercise sessions were green and those taken immediately after
exercise were red. Participants recorded the time that the
preexercise capsule was taken when they arrived at the exercise
facility. The postexercise pill was taken immediately after
completing the exercise session, and the time was recorded.
Randomization to the three drug-intervention arms was
stratified for use of hormonal contraceptive therapy. The
University of Colorado Denver Research Pharmacy managed
the randomization process, maintained all drug intervention
records, and prepared and dispensed study drug packets.
Exercise training intervention
Allwomeninthestudyparticipated ina9-monthweight-bearing
exercise training program. The general structure of the exercise
training program was similar to programs used in previous
studies that resulted in increases in BMD.
(16,17) Participants were
instructed to attend at least three supervised exercise sessions
per week. The exercise program included weight-bearing
endurance exercises (eg, walking, jogging, rope jumping, and
stair climbing/descending), weight-supported endurance exer-
cisethatgeneratesrelativelyhighmuscleforces(eg,rowing),box
jumps (eg, step up onto a platform and jump off, 2-ft landing),
and upper and lower body resistance exercises. The lower body,
biceps, and triceps exercises were performed unilaterally.
Exercise was prescribed initially at a moderate intensity (60%
to 70% of maximal heart rate, three sets of 12 to 15 repetitions at
60% to 70% of 1-repetition maximum) for a total of 30min/day.
The duration and intensity of exercise were increased gradually
on an individualized basis, with exercise prescriptions updated
weekly. Box-jump height started at 8 inches and was increased
by 2inchesas tolerated toamaximum of16inches. Thegoalwas
to perform a combination of high-intensity endurance (80% to
85% of maximal heart rate), resistance (three sets of 8 to 10
repetitions at 70% to 80% of 1-repetition maximum), and
jumping exercises for a total exercise time of approximately
45min/day over the last 3 months of the program, not including
time to warm up and cool down.
BMD and body composition
BMD of the total body, lumbar spine (L2–L4), and proximal femur
(total, neck, trochanter, and shaft) was measured by dual-energy
x-ray absorptiometry (DXA) on a Hologic Delphi-W instrument
(Hologic, Inc., Bedford, MA, USA) at baseline and after 9 months
of exercise training. The total-body scan also provided measures
offatmassandfat-freemass.Inourlaboratory,thecoefficientsof
variation (CVs) for lumbar spine, total-hip, femoral neck,
trochanter, and shaft (ie, subtrochanteric region) BMD are
(mean SD) 1.2% 0.8%, 0.8% 0.6%, 1.9% 0.9%, 1.5% 
1.0%,and1.1%  0.6%,respectively.CVsforfat-freemassandfat
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procedures included spine phantom scans daily, whole-body
phantom scans three times per week, air scans once a week, and
tissue bar scans once a month.
Statistical analyses
Because there have been no previous intervention studies of the
effects of regular NSAID use on BMD adaptations to exercise, this
was a physiologic study of the effects that occur when there is
compliance with the exercise program. Therefore, the primary
data analysis was per protocol rather than intent to treat.
Compliance was defined as attending at least 80% of the
prescribedexercisesessions overthe9-monthintervention(ie,at
least 2.4 per week).
Homogeneity across groups at baseline was verified by one-
way analyses of variance for age, BMI, weight, fat mass, fat-free
mass, and BMD. A chi-square test for equal proportions across
groups was applied to ethnicity and hormonal contraception
use. The baseline data also were examined for differences by
hormonal contraception use with two-group t tests, chi-square
tests, or exact chi-square tests as appropriate.
The effects of ibuprofen on the BMD responses to exercise
training were evaluated by analysis of covariance (ANCOVA),
regressing the 9-month change in BMD on baseline BMD and
group (IBUP/PLAC, PLAC/IBUP, and PLAC/PLAC). The same
method was used to assess the effects of age, change in body
weight, and use of hormonal contraception. Although p values
were not adjusted for multiple comparisons, we protected the
type I error rate by requiring a priori that effects be significant for
more than one BMD region and by testing for any differences
across groups before testing pair-wise differences. Pair-wise
comparisons were considered significant only when both the
global F and the pair-wise comparison were significant at an
alpha level .05 or less. Data are presented as mean SD, unless
otherwise specified.
Results
Of the 95 volunteers randomized to the drug treatment arms,
73 completed the 9-month exercise program, and 54 completed
at least 80% of the prescribed sessions. The attrition and
noncompliance rates were higher than expected, but it is
unlikely that this was related to the intervention per se. Rather,
because the study was carried out during a time interval when
the university was moving to a new campus, these factors were
negatively influenced by relocation of the exercise training
facility twice during the study (ie, from the old campus to an
interim off-campus facility and then to the new campus).
The treatment groups in the subset of participants who were
compliant with the intervention were well matched on baseline
characteristics (Table 1). There were no significant differences in
baseline characteristics between users and nonusers of
hormonal contraception (Table 2).
Exercise intervention
There were no significant differences among the groups in the
amount of exercise performed during the intervention. Among
those who were compliant, the average exercise frequency was
3.4 0.6,3.4 0.6,and3.6 0.6daysperweekintheIBUP/PLAC,
PLAC/PLAC, and PLAC/IBUP groups, respectively. The average
volume of exercise performed by all participants in the second
month of the study (after participants had become accustomed
to the equipment) and in the eighth month of the study (before
finalfollow-uptesting began)issummarizedinTable3.Treadmill
walking/running was the most commonly performed endurance
exercise.
Across the entire 9-month exercise program, the time interval
between the preexercise and postexercise drug doses averaged
2.37 0.44, 2.45 0.46, and 2.55 0.46 hours (p¼.55) for the
IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively.
Because the postexercise capsule was taken immediately on
completion of an exercise session, this indicates that the pre-
exercise capsule typically was taken about 1.5 hours before an
exercise session. Pill compliance, assessed as the percentage of
prescribed doses based on exercise frequency, was 83% 20%,
80% 24%, and 86% 16% in the IBUP/PLAC, PLAC/PLAC, and
PLAC/IBUP groups, respectively.
Changes in body composition
There were no significant differences among the groups in the
changes in fat mass or fat-free mass in response to exercise
training (Fig. 1). The changes in fat mass were –2.2 2.5kg,
 2.0 2.2kg, and  1.3 1.8kg in the IBUP/PLAC, PLAC/PLAC,
and PLAC/IBUP groups, respectively. The respective changes in
fat-free mass were 0.4 1.3kg, 0.8 1.1kg, and 0.8 1.1kg.
Changes in BMD
As hypothesized, among women who were compliant with the
exercise intervention, taking ibuprofen before exercise (IBUP/
PLAC) impaired the increases in BMD when compared with
taking ibuprofen after exercise (PLAC/IBUP), although the effect
at the lumbar spine was not statistically significant (Fig. 2, top
panel). The differences (mean SE, adjusted for baseline BMD)
between these two groups in the changes in BMD were
0.013 0.008g/cm
2 for the lumbar spine (p¼.100), 0.020 
0.005g/cm
2 for the total hip (p¼.001), 0.018 0.008g/cm
2
for the femoral neck (p¼.020), 0.012 0.006g/cm
2 for the
trochanter (p¼.030), and 0.024 0.009g/cm
2 for the femoral
shaft (p¼.007). The inclusion of age, change in body weight, or
use of hormonal contraception in the analysis model did not
change the results. As would be expected, the magnitude of
differences between the groups was diminished by the inclusion
of participants who were not compliant with exercise (Fig. 2,
bottom panel). However, the pattern of group differences
remained.
In contrast to the hypothesis, the group that received only
placebo treatment (PLAC/PLAC) did not have the most robust
increases in BMD. Increases in BMD in this group tended to be
only slightly, but not significantly, larger than in the IBUP/PLAC
group in some regions (Fig. 2, top panel). Unexpectedly, the
increases in BMD adjusted for baseline BMD were significantly
greater in the PLAC/IBUP group than in the PLAC/PLAC group at
the femoral neck (difference 0.019 0.007g/cm
2, p¼.010), hip
(0.018 0.005g/cm
2, p¼.001), trochanter (0.013 0.005g/cm
2,
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2, p¼.020); the
difference at the lumbar spine was not statistically significant
(0.006 0.007g/cm
2, p¼.431).
Discussion
The aim of this study was to determine whether the regular use
of ibuprofen before or after exercise sessions influences the BMD
adaptations to exercise training. The scientific basis for the study
was the evidence from animal studies that the acute increase in
bone formation in response to mechanical loading is markedly
inhibited when NSAIDs are administered before, but not after,
mechanical loading.
(7,9,20) Consistent with this evidence, we
found that taking ibuprofen before exercise resulted in the least
favorable adaptations in BMD. However, in contrast to our
expectation that the PLAC/PLAC and PLAC/IBUP groups would
have similar increases in BMD, we found that the largest
increases occurred in the group that took ibuprofen immediately
after completing the exercise sessions.
Ibuprofen and other nonselective and selective COX inhibitors
are thought to influence bone metabolism by blocking the
production of PGE2.
(28) The actions of PGE2 in bone are complex.
Table 1. Baseline Characteristics of Compliant Participants
N (%) or mean SD and p values for comparisons by group
Variable Category IBUP/PLAC PLAC/PLAC PLAC/IBUP p Value
Hormonal contraceptives No 9 (52.9) 14 (60.9) 7 (50.0) 0.784
Yes 8 (47.1) 9 (39.1) 7 (50.0)
Ethnicity White 14 (82.4) 20 (87.0) 14 (100.0) 0.404
Hispanic 2 (11.8) 2 (8.7) 0 (0.0)
Other 1 (5.9) 1 (4.3) 0 (0.0)
Age, years 30.8 6.2 33.2 5.3 32.1 5.0 0.418
BMI, kg/m
2 24.0 4.5 23.6 2.8 23.6 3.0 0.935
Height, cm 165.0 8.5 167.2 7.8 165.2 5.7 0.580
Weight, kg 66.5 9.3 67.0 9.8 64.9 9.4 0.795
Fat mass, kg 21.5 5.2 22.5 6.7 21.0 7.3 0.775
Fat-free mass, kg 45.0 5.1 44.5 5.1 43.8 5.2 0.821
BMD, g/cm
2
Total hip 1.005 0.112 0.982 0.128 0.978 0.116 0.782
Femoral neck 0.896 0.127 0.886 0.114 0.915 0.125 0.793
Trochanter 0.755 0.105 0.760 0.098 0.754 0.127 0.980
Shaft 1.184 0.118 1.150 0.166 1.128 0.130 0.552
Lumbar spine 1.092 0.124 1.130 0.122 1.061 0.152 0.293
IBUP¼ibuprofen; PLAC¼placebo; BMI¼body mass index; BMD¼bone mineral density.
Table 2. Baseline Characteristics by Use of Hormonal Contraceptive Therapy
Mean SD or n (%) and p values for comparisons by OC uUse
Variable Category Yes No p Value
Ethnicity White 20 (83.3) 28 (93.3) 0.653
Hispanic 3 (12.5) 1 (3.3)
Other 1 (4.2) 1 (3.3)
Age, years 31.0 4.6 33.1 6.0 0.173
BMI, kg/m
2 22.9 2.2 24.3 4.1 0.119
Height, cm 166.7 6.8 165.4 8.1 0.515
Weight, kg 64.5 8.2 67.8 10.2 0.204
Fat mass, kg 20.2 5.2 23.1 6.9 0.095
Fat-free mass, kg 44.3 4.7 44.6 5.4 0.786
BMD, g/cm
2
Total hip 0.986 0.128 0.990 0.113 0.890
Femoral neck 0.901 0.131 0.894 0.112 0.832
Trochanter 0.751 0.112 0.762 0.103 0.714
Shaft 1.154 0.143 1.156 0.144 0.947
Lumbar spine 1.098 0.140 1.102 0.126 0.925
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and inhibit bone formation and resorption may relate to the
distribution of the four prostaglandin receptor subtypes in
bone.
(21) Because the major effects of PGE2 in bone are to
stimulate both formation and resorption, blocking PGE2
production with NSAIDs would be expected to have antiforma-
tion and antiresorptive effects.
(28) Accordingly, the net effect on
BMD could be deleterious or favorable depending both on
relative balance between the antiformation and antiresorptive
activities and on the state of bone turnover.
Because of the potential antiresorptive actions of COX
inhibitors, several animal studies have evaluated whether
NSAIDs prevent the bone loss that occurs following ovariectomy
as a result of the increase in bone turnover. Indeed, in one of
the early studies, 6 weeks of naproxen treatment reduced
ovariectomy-related bone loss by approximately 70% in adult
rats.
(18) However, in a follow-up study, the same investigators
found that 12 weeks of naproxen was ineffective in preventing
ovariectomy-related bone loss in adult rats.
(14) Others have
confirmed that NSAIDs are ineffective
(13) or only partially
effective
(10,12) in attenuating ovariectomy-related decreases in
bone volume or BMD.
Chronic NSAID use also has been found to cause bone loss in
laboratory animals. In ovariectomized adult rats, 24 weeks of
indomethacin treatment caused greater decreases in lumbar
spine BMD, trabecular bone volume, and trabecular thickness
thanvehicle treatment.
(30)Similarly,treatment ofyoungratswith
ibuprofen for 28 days had an independent adverse effect on
trabecular bone volume in intact, ovariectomized, ovariecto-
mized estrogen-treated, and ovariectomized tamoxifen-treated
animals.
(32) Male gonad-intact rats treated with a COX-2 selective
inhibitor for 30 days had an increase in bone resorption and a
decrease in formation but, paradoxically, BMD was preserved.
(31)
However, as with the studies of naproxen discussed earlier,
(14,18)
a longer duration of treatment with a COX-2 selective inhibitor
may be necessary to determine the true effects of COX-2
inhibitors on BMD. These studies of laboratory animals
highlight the complex and variable effects of NSAIDs on bone
metabolism, which may be influenced by the age of the animal,
bone turnover state, type and dose of NSAID, and duration of
treatment.
In contrast to the variable effects of chronic NSAID treatment
on bone metabolism in animals, a consistent finding is that
NSAIDsimpairthebone-formationresponsetoacutemechanical
loading. PGE2 was identified as playing a role in mechanical
transduction in bone more than 20 years ago.
(33) Key evidence
that prostaglandins are essential for bone formation came from
in vivo mechanical loading experiments in which the expected
osteogenic response to mechanical loading was absent when
indomethacin was administered.
(27) Subsequent studies
revealed that the bone-formation response is mediated by
COX-2.
(2,9) However, in mice lacking COX-2 (ie, null mutation), a
Table 3. Average (Mean SD) Volume of Exercise Performed in Months 2 and 8 of the 9-Month Intervention
Weeks 5–8 Weeks 29–32
Repetitions Weight, lb Repetitions Weight, lb
Resistance exercises
Leg extension
a 39 10 44 16 26 12 52 26
Leg flexion
a 41 94 4  14 26 13 52 26
Leg press
a 35 19 86 52 28 15 128 61
Lat pulldown 42 9 107 33 27 14 131 62
Bench press 41 86 3  20 26 13 79 36
Overhead press 40 84 0  13 26 12 49 21
Biceps curl
a 40 82 2  62 5  13 24 11
Triceps extension
a 41 81 5  52 7  13 22 12
Seated row 32 20 57 38 26 14 88 42
Box jumps, number/week 110 33 121 60
Height, in 10.0 0.4 15.7 1.0
Stairs, flights/week 4.3 3.4 8.6 4.0
Weight-bearing endurance exercises
Duration, minutes/week 97.3 40.0 103.0 73.0
Heart rate, beats/min 154.6 12.2 157.0 11.3
aExercises performed unilaterally.
Fig. 1. Changes in fat mass and fat-free mass in response to exercise
training. Values are mean SE.
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achieved through a compensatory increase in COX-1.
(1) This
suggests that nonselective COX inhibitors may suppress bone
formation to a greater extent than COX-2 selective inhibitors
when used chronically.
The timing of NSAID administration relative to mechanical
loading has been found to be an important determinant of the
bone-formation response. Chow and colleagues were the first to
observe that the increase in bone formation in adult rats was
suppressed by indomethacin when it was administered before,
but not after, mechanical stimulation.
(7) This was confirmed
subsequently in a study in which a COX-2 inhibitor, NS-398, was
administered to rats before or after in vivo mechanical loading of
the tibia.
(20) NS-398 administered 3 hours or 30 minutes before
mechanical loading significantly dampened the bone-formation
response, whereas administration 30 minutes after loading did
not.
Although there is consistent evidence from studies of animals
that the administration of NSAIDs prior to mechanical loading
blocks the bone-formation response, a limitation is that the
studies have assessed the response to only a single bout of
loading. To our knowledge, this study is the first, in humans or
animals, to evaluate whether NSAID use, and specifically the
timing of use (i.e., before versus after bone-loading exercise), is
an important determinant of the adaptation of BMD to repeated
mechanical stimulation (i.e., exercise training). Based on the
studies of acute loading in animals,
(7,20) we hypothesized that
taking ibuprofen before exercise sessions would blunt the
adaptation in BMD but that taking ibuprofen after exercise
sessions would not. The observation that the least favorable
changes in BMD tended to occur in the group that took
ibuprofen before each exercise training session was interpreted
as being consistent with the evidence that COX inhibition prior
to loading blocks bone formation.
(7,9,20,27) However, the robust
increases in BMD in the group that took ibuprofen after exercise
were not anticipated. Rather, it was expected that the increases
in BMD would be similar in the PLAC/PLAC and PLAC/IBUP
groups.
Fig. 2. Relativechanges (%) in bonemineraldensity (BMD)adjustedfor baselineBMDin responseto exercise trainingin participants whowere compliant
with the intervention (top panel) and in all participants who finished the intervention (bottom panel). Values are mean SE.
 
Different from the other
groups, p .01.
yDifferent from the other groups, p .05.
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in the placebo-only group should be considered. One possibility
is that because they did not receive any NSAID treatment, the
physical discomforts that sometimes occur with vigorous
exercise training may have caused them to reduce their physical
activity level outside the exercise program. We think that this
was unlikely because all participants were instructed to take
acetaminophen if they had a need for analgesic therapy. This
recommendation was based on the long-standing belief that, in
contrast to NSAIDs, the mechanism by which acetaminophen
relieves pain does not involve COX suppression. However, recent
evidence suggests that acetaminophen does, indeed, act
through COX-related mechanisms.
(11,15) To our knowledge, the
effect of acetaminophen on the bone-formation response to
loading has not been studied. However, if effects are similar to
those of NSAIDs, and if the group on placebo-only therapy used
more acetaminophen than the groups on ibuprofen, then this
may have contributed to the small changes in BMD in the
placebo group.
Potential reasons for the larger than expected increases in
BMD inthe group that took ibuprofen after exercise sessions also
should be considered. High-intensity endurance and resistance
exercise stimulates increases in serum inflammatory cyto-
kines.
(22,25,26) For example, serum interleukin 6, which is a
potent stimulator of bone resorption,
(24) was increased approxi-
mately sevenfold 1 hour after a bout of vigorous resistance
exercise.
(25) In general, intense exercise generates increases in
inflammatory cytokines that peakwithin afewhours of cessation
of exercise.
(22) If the exercise performed in the current study
generated increases in proresorptive cytokines, it is possible that
the benefit on BMD of taking ibuprofen immediately after
exercise sessions was via the suppression of inflammatory-
mediated bone resorption. Further research will be needed to
explore such mechanisms.
The bulk of evidence from studies of animals suggests that
NSAIDs do not have favorable effects on bone. Accordingly, it
might be predicted that chronic NSAID use would be associated
with low BMD values in humans. Associations of NSAID use with
BMD, bone turnover markers, and/or fracture risk have been
evaluated in the Study of Osteoporotic Fractures,
(3) Rancho
Bernardo Study,
(23) Health ABC Study,
(4) and Canadian Multi-
centre Osteoporosis Study.
(29) In all these studies, analysis of
covariance was used to adjust for an array of parameters likely
to be associated with the outcomes of interest. After such
adjustments, there was no evidence that NSAID use influenced
bone turnover or nonvertebral fracture risk. However, in all four
of the cohort studies, there was some evidence for increased
BMD levels in some groups of NSAID users when compared with
nonusers. As an example, in the Rancho Bernardo Study of
women aged 44 to 98 years,
(23) regular use of proprionic acid
NSAIDs was associated with increased BMD levels of the hip (2%
to 3%) and lumbar spine ( 9%).
(23) This type of favorable
association of NSAID use with BMD in humans is seemingly in
contrast with the unfavorable effects of NSAIDs on bone
metabolism in laboratory animals. However, in the Canadian
Multicentre Osteoporosis cohort study,
(29) favorable effects of
COX-2 selective inhibitors on BMD were apparent only in
postmenopausal women and primarily in those on estrogen-
based hormone therapy. In contrast, men who used COX-2
selective inhibitors had significantly lower BMD levels than men
who did not. Such findings support the concept that bone
turnover state may be an important determinant of the effects
of NSAIDs on bone metabolism. In high-turnover conditions
(e.g., postmenopausal women not on hormone therapy), the
antiresorptive effects of NSAIDs may predominate and have a
beneficial effect on BMD, whereas in low-turnover conditions
(e.g., men), the antiformation effects may predominate and have
an adverse effect on BMD.
This study had some limitations. Participants were instructed
to use acetaminophen for pain relief when needed, but there is
emerging evidence that acetaminophen has COX inhibitory
effects.
(11,15) No data were collected regarding the use of this
medication. Additionally, we did not control for changes in
physical activity outside the exercise intervention; between-
group differences in nonintervention exercise or activity could
have confounded the findings of the study. This was a small
study of premenopausal women, and the results may not
be applicable to other patient groups with different rates of
bone turnover. Because this was the first intervention study of
the effects of the timing of NSAID use on adaptations of bone
to mechanical loading, many questions remain regarding the
potential influence of the type of NSAID, dose, and specific
timing of use relative to exercise.
In summary, taking 400mg of ibuprofen immediately after
exercise sessions augmented the beneficial adaptations of BMD
to 9 months of exercise training when compared with taking
ibuprofen before exercise or with placebo therapy. Because of
the common use of over-the-counter NSAIDS among people
who exercise regularly, such findings may have important public
healthramifications. However,furtherresearch isneededbothto
confirm the results of this first preliminary study of the timing of
NSAID use on skeletal adaptations to exercise training and to
determinetheextenttowhichthefindingscanbegeneralizedto
other types and doses of NSAIDs and populations other than
premenopausal women. It also will be necessary to determine
the mechanisms by which timing of NSAID use relative to
exercise influences skeletal adaptations.
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